Ceruvia Raises $8 Million to Advance Phase 1/2 Trial of Cluster Headache Therapy

Ceruvia Lifesciences has raised $8 million to fund the next stage of clinical development for BOL-148, its proprietary non-hallucinogenic LSD... Read More

The post Ceruvia Raises $8 Million to Advance Phase 1/2 Trial of Cluster Headache Therapy appeared first on citybiz.